Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clonidine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Clonidine | DRUG | - |
Please contact site for information.
Clonidine is a small molecule being investigated for use in Opioid-Related Disorders, specifically for opiate detoxification. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being studied to address conditions related to opioid and substance-related disorders.
Clonidine is a small molecule that acts on alpha-2 adrenergic receptors. It is being studied for its potential role in managing Opioid-Related Disorders, particularly in the context of opiate detoxification. The drug's mechanism involves modulating adrenergic signaling, which may help alleviate withdrawal symptoms.
Clonidine is being developed by National Healthcare Corp., a company traded under the ticker symbol NHC. The company is conducting clinical research on this small molecule for the treatment of Opioid-Related Disorders, with the drug currently in Phase 2 development.
Clonidine is in Phase 2 clinical development for Opioid-Related Disorders. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its safety and efficacy in opiate detoxification, with one completed Phase 2 trial.
Clonidine has been studied in one clinical trial with the identifier NCT00000279, titled "Novel Medications for Opiate Detoxification - 4." This Phase 2 trial was completed in the United States and enrolled adults aged 18 years and older with Opioid-Related Disorders and Substance-Related Disorders.